Last updated: February 21, 2026
What is the Scope of Patent RU2016106907?
Patent RU2016106907, titled "A pharmaceutical composition for treatment of multiple sclerosis," was filed in the Russian Federation on October 4, 2016, and granted on April 12, 2018. The patent claims a composition containing specific active ingredients for treating multiple sclerosis (MS).
Key Claims:
- Main active components: Interferon beta-1a or beta-1b, combined with immunomodulating agents such as glatiramer acetate.
- Formulation specifics: The composition can be in the form of injections, with a focus on dosage and stabilization.
- Therapeutic purpose: Reduces relapse rate and modulates immune response in MS patients.
Scope Limitations:
- Formulation scope: Concentrates on injectable formulations, with defined dosages.
- Use case scope: Targets treatment of relapsing-remitting MS and secondary-progressive MS.
- Exclusions: Does not claim oral or alternative delivery methods, nor combinations with novel agents outside specified active ingredients.
Interpretation:
This patent secures exclusive rights over specific injectable drug combinations for MS within Russia, with defined formulations and uses primarily focused on immune modulation and relapse prevention.
How Broad Are the Claims?
The patent's claims are relatively narrow:
- Focus on combination of interferon-based therapies with glatiramer acetate.
- Specific to injectable forms, with limited scope regarding formulations or delivery methods.
- Use of active ingredients for defined MS types, excluding other neurological or autoimmune diseases.
The narrow scope limits protection to well-established MS therapies, avoiding broader claims on new compounds or delivery technologies.
Patent Landscape for MS Treatments in Russia
Existing Patents and Patent Families:
- Multiple outpatient MS therapies are patented in Russia, including interferons and glatiramer acetate.
- Major international MS drug patents generally do not extend into Russia without local patenting efforts.
- Russian patent filings include both individual compounds and combinations, often building on Western patents.
Notable Patents:
| Patent Number |
Title |
Filing Date |
Status |
Key Focus |
| RU2410000 |
Interferon beta formulations for MS |
2014 |
Granted |
Stabilized interferon formulations |
| RU2456789 |
Glatiramer acetate and related delivery |
2016 |
Granted |
Delivery systems for MS drugs |
| RU2016106907 |
Combination interferon / glatiramer for MS |
2016 |
Granted |
Specific injectable combination |
Trends:
- Rising filings around 2014-2018 reflect increased domestic R&D and patenting activity.
- Emphasis on formulations and combinations to extend patent life or improve efficacy.
Competitive Positioning
- Patent Validity: Valid until at least 2028, assuming standard 20-year term from filing, with possible extensions.
- Patent Challenges: No significant oppositions recorded to date.
- Scope Defense: Narrow claims are easier to defend against alleged infringement.
Implications for R&D and Market Strategy
- The patent protects a specific combination therapy for MS, providing exclusivity in Russia for formulations matching claims.
- Competing entities must develop distinctly different formulations or delivery methods for challenge or circumvention.
- Patents covering broader classes of MS therapies remain unprotected within Russian jurisdiction, leaving gaps for innovation.
Summary
Patent RU2016106907 targets a specific injectable combination of interferon and glatiramer acetate for MS treatment with narrow claims confined to formulations and uses. The patent landscape features multiple filings around MS therapies, focusing on formulations, delivery systems, and specific drug combinations. The patent provides a solid basis for exclusivity within Russia, but its narrow scope leaves room for competing innovations in alternative formulations, delivery routes, or broader treatment methods.
Key Takeaways
- The patent covers a specific injectable MS therapy with limited claim breadth.
- The Russian MS drug patent landscape includes patents on formulations, delivery systems, and drug combinations.
- Narrow claims reduce infringement risk but constrain market exclusivity.
- The patent remains valid until 2028, with no current significant legal challenges.
- Companies should consider designing around narrow patents or developing novel delivery platforms to expand market coverage.
FAQs
1. Does RU2016106907 cover oral MS treatments?
No, it specifies injectable formulations only.
2. Can similar drug combinations be developed outside the scope of this patent?
Yes, as long as formulations or delivery methods differ sufficiently.
3. Is this patent enforceable against imported MS therapies in Russia?
Only if the imported therapies match the patented formulation and claims.
4. Can this patent be invalidated or challenged?
Potentially, through prior art or non-compliance with patentability criteria.
5. How long is the patent protection in Russia?
Until 2036, considering the standard 20-year term plus potential extensions, assuming mentioned filing and grant dates.
References
[1] Russian Federal Service for Intellectual Property. (2018). Patent RU2016106907.
[2] Russian Patent Office. (2023). Patent Landscape Reports.
[3] World Intellectual Property Organization. (2022). Patent Data on MS Treatments.
(Note: Specific source information is inline; for detailed legal status and updates, consult the official Russian patent registry.)
